Visão geral da empresa
Fortrea Holdings Inc. operates globally as a contract research organization dedicated to delivering comprehensive biopharmaceutical product and medical device development solutions to a diverse clientele within the pharmaceutical, biotechnology, and medical device sectors. Within the broader Healthcare sector, the company specifically functions inside the Biotechnology industry, providing specialized services such as clinical pharmacology through clinical research units and external partnerships that support the product lifecycle from early development through later-stage trials. The enterprise maintains a substantial operational footprint supported by a workforce of 13,871 employees, underpinned by a market capitalization of $877.03 million and trailing twelve-month revenue of $2.72 billion. These financial dimensions, particularly the market cap exceeding $877 million alongside annual revenues near $2.72 billion, indicate that Fortrea holds a significant position within the contract research landscape, serving as a critical infrastructure partner for major drug developers seeking external expertise in clinical trials and medical device innovation.
Saúde financeira
The company reported total revenue of $2.72 billion for the trailing twelve months, yet generated a net income of -$986.2 million, highlighting a substantial divergence between top-line generation and bottom-line profitability that points to a cost structure with heavy overheads or significant one-time charges impacting the bottom line. Despite the negative net income, the organization reported EBITDA of $41.50 million and generated free cash flow of $196.05 million, which suggests a degree of operational cash generation capability that provides financial flexibility for capital allocation even in the absence of reported net earnings. The gross margin stands at 18.5%, reflecting the cost of goods sold relative to revenue in a service-intensive business model, while the operating margin is compressed to just 1.3%, indicating that operating expenses are consuming nearly all gross profits before interest and taxes. The profit margin is negative at -36.2%, confirming that for every dollar of revenue, the company retains a loss after all expenses, a common characteristic in early-stage or high-growth biotech services but one that warrants monitoring regarding long-term sustainability. Liquidity and leverage metrics reveal a balance sheet with $174.60 million in cash against $1.12 billion in debt, resulting in a debt-to-equity ratio of 198.26, which characterizes a highly leveraged balance sheet typical of capital-intensive research organizations. The current ratio of 0.98 indicates that current assets barely cover current liabilities, suggesting tight short-term liquidity conditions where the company must efficiently manage working capital to meet its obligations. Return on equity is -102.4% and return on assets is -0.6%, metrics that collectively reveal that management has not yet achieved positive returns on the substantial capital invested in the business, reflecting the inherent challenges of the biotechnology research and development environment.
Avaliação de valorização
The valuation metrics present a complex picture where the P/E ratio (TTM) is listed as N/A due to the negative net income, while the forward P/E is 9.91, implying that the market anticipates a normalization of earnings in the future that would result in a significantly lower valuation multiple compared to the historical inability to calculate a trailing multiple. The price-to-book ratio is 1.55, indicating that the market values the company's equity at 1.55 times its book value, suggesting a modest premium over the net asset value which may reflect intangible assets like intellectual property or future revenue potential not fully captured on the balance sheet. Alternative valuation measures include a price-to-sales ratio of 0.32 and an EV/EBITDA of 43.85, where the low price-to-sales figure suggests the company trades at a fraction of its revenue, potentially reflecting investor caution regarding the high debt load and negative earnings, while the high EV/EBITDA highlights the premium investors are willing to pay relative to earnings before interest, taxes, depreciation, and amortization. The stock's price volatility is captured by a 52-week high of $18.67 and a low of $3.97, with the current trading price situated significantly below the 52-week high, reflecting a downward trend over the past year. The beta value of 1.77 indicates that the stock's price volatility is substantially higher than the broader market, moving approximately 1.77 times as much as the market index, which introduces elevated risk for investors sensitive to market fluctuations.
Growth & Income
The revenue growth year-over-year is -5.2%, while earnings growth is listed as N/A due to the current loss position, implying that the company is currently shrinking its top line rather than expanding it, which is a concerning trend for a large-cap contract research organization. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that instead of distributing cash to shareholders, the entity retains all cash flows to fund operations and debt service given its highly leveraged status. This lack of income distribution combined with negative revenue growth suggests a growth and income profile that relies entirely on operational turnaround and debt reduction rather than shareholder returns or organic expansion at this stage.